Tribe Public’s Post

Learn more about the innovative "#PulsePrime" approach with Roger Waltzman, Chief Medical Officer at Indaptus Therapeutics (NASDAQ: INDP), as he explains how the novel therapy, Decoy20, is set to revolutionize #cancertreatment. This method involves administering a rapid, potent dose of engineered bacteria directly into the bloodstream—unlike traditional therapies, this "pulse" is brief yet effective enough to activate and prime the #immunesystem without the prolonged exposure that can lead to side effects. This intermittent dosing strategy aims to enhance the immune system's responsiveness and reduce potential adverse reactions, offering new hope to more patients battling advanced cancer. Watch to learn more about how they're harnessing the body's defenses to fight cancer more effectively. https://lnkd.in/gB97iNaV #IndaptusTherapeutics #CancerResearch #Decoy20 #biotech #ImmunoOncology

Learn more about the innovative "#PulsePrime" approach with Roger Waltzman, Chief Medical Officer at Indaptus Therapeutics (NASDAQ: INDP), as he explains how the novel therapy, Decoy20, is set to revolutionize #cancertreatment. This method involves administering a rapid, potent dose of engineered bacteria directly into the bloodstream—unlike traditional therapies, this "pulse" is brief yet effective enough to activate and prime the #immunesystem without the prolonged exposure that can lead to side effects. This intermittent dosing strategy aims to enhance the immune system's responsiveness and reduce potential adverse reactions, offering new hope to more patients battling advanced cancer. Watch to learn more about how they're harnessing the body's defenses to fight cancer more effectively. https://lnkd.in/gFAVuwMi #IndaptusTherapeutics #CancerResearch #Decoy20 #biotech #ImmunoOncology

Make sure to tune in to learn more about Health Catalysts abstraction capabilities and the work we’ve been doing to leverage AI to make abstraction faster and more accurate!

Buy-and-Build: How to Double Your Money by Playing the Multiples Game

#ForesightDx is on a mission to improve the lives of cancer patients worldwide through #innovative diagnostics. Identifying minimal residual disease from liquid biopsy following #cancer treatment is a promising method for earlier relapse detection. Minimal residual disease (#MRD) can be measured using circulating tumor DNA (#ctDNA) to determine whether a patient is likely to relapse. The ability to detect even the smallest traces of ctDNA after treatment could inform #therapeutic decisions aimed to control or cure cancer. Foresight CLARITY accurately detects MRD as early as end of treatment when ctDNA levels are at their lowest and often missed by conventional imaging and liquid biopsy methods. With Foresight CLARITY's unprecedented #sensitivity and superior prognostic #utility, get the data you need to see clearly and act decisively. Watch this video to learn more about Foresight CLARITY: https://t.ly/K_GOu Learn about our partnership with Allogene Therapeutics: https://t.ly/Zn0h8 Read our recent research and publications: https://lnkd.in/g7n_zHb6 #PrecisionMedicine #ForesightCLARITY #SeeClearlyActDecisively #CancerDiagnostics #LiquidBiopsy #lymphoma #solidtumor #oncology #hematology #clinicalresearch

Veru Inc.( $VERU) Advances Muscle Preservation Research with Enobosarm and Strengthens Financial Position https://lnkd.in/eJTqk_CR #stockstowatch #stocksinnews #investors #daytrader #PrismMarketView #PrismMediaWire #PrismDigitalMedia

High-throughput formation of 3D HepaRG™ model is now available! Discover the method of high throughput formation of HepaRG spheroids and how to isolate single spheroids without impacting their functionalities in one of the three sessions of our webinar: The use of HepaRG™ cells for in vitro liver fibrosis modelling- Leo Van Grunsven High throughput formation of HepaRG™ spheroids and preparation of assay-ready plates using spheroONE™- Cellenion Evaluation of drug-induced liver toxicity in a 3D HepaRG™-based microphysiological human liver model- Dynamic42 📅 Date: February 15th, 2024 🕒 Time: 10:00 am – 12:00 pm CET   📌 Reserve your spot now: https://lnkd.in/e426c3xk #HepaRG #Fibrosis #liver #spheroids #3D #MPS #organonachip

The advancement of medical technology has improved the screening of colon, prostate, and breast cancer, but what about the lungs? Earlier this spring, Alan Lucas had the opportunity to present on behalf of Navigation Sciences at this year’s LSI Emerging MedTech Summit. Alan spoke about the importance of utilizing screening technology for early-stage lung cancer detection, early surgical intervention, and where the NaviSci System can fill an essential need by providing real-time precision surgical navigation. Watch Alan’s presentation from LSI below. https://lnkd.in/gxqd2fK6 

MEDICAL UPDATE: By way of explaining my erratic publishing schedule: So far this year I've; been diagnosed with Parkinson's, had a brain biopsy, been diagnosed with non-Hodgkin's B Cell Lymphoma in the brain (not related to the Parkinson's), had a relatively mild Flu (which delayed the following) and, started Chemotherapy (two days a month for six months). The prognosis for the Lymphoma is positive but Stevie Wright's "Hard Road" does come to mind! 1965 was a seminal year for Australian Music! To make this Top 11 (tie), the lowest chart position achieved had to be a #3. There are #4 releases that reach #1, and two of those were recorded overseas. Only one group from the 1964 chart appears in the 1965 Top 11. In total there are only four groups in this Top 11. All but one of those has multiple entries! There is only one individual in the Top 11. You can probably guess some of that but "do yourself a favour" (sorry Molly!) and take a listen to this episode.

What’s Your Annuity Exit Strategy? View the Annuity Spotlight What's Your Annuity Exit Strategy? … dated December 17, 2023. https://lnkd.in/gCjMe3Bm